Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- aminocaproic acid
- tretinoin
Interactions between your drugs
aminocaproic acid tretinoin
Applies to: aminocaproic acid, tretinoin
MONITOR CLOSELY: Coadministration of tretinoin (all-trans retinoic acid) with antifibrinolytic agents may increase the risk of thrombosis. Tretinoin is associated with a risk of both venous and arterial thrombosis during the first month of treatment that may involve any organ system. Cases of fatal thrombotic complications have been reported rarely in patients concomitantly treated with tretinoin and antifibrinolytic agents.
MANAGEMENT: Caution is advised when tretinoin is prescribed in combination with antifibrinolytic agents such as aminocaproic acid, aprotinin, or tranexamic acid. Patients should be advised to seek medical attention immediately if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, hemoptysis, hematuria, sudden loss of vision, and pain, redness or swelling in an extremity.
References (3)
- (2001) "Product Information. Vesanoid (tretinoin)." Roche Laboratories
- (2022) "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc
- Hashimoto S, Koike T, Tatewaki W, et al. (1994) "Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage." Leukemia, 8, p. 1113-5
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Advate
Advate (antihemophilic factor) is used to prevent bleeding episodes in adults and children with ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Adzynma
Adzynma (ADAMTS13, recombinant-krhn) is a human recombinant protein that may be used to prevent or ...
Alhemo
Alhemo is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...
Alphanine SD
Alphanine SD is used for factor ix deficiency, hemophilia b
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.